DOI: https://doi.org/10.36347/sasjm.2025.v11i12.010

Pages: 1197-1203

Background: Dengue is a viral infection predominantly found in tropical regions, caused by the dengue virus and transmitted to humans through the bites of Aedes aegypti and Aedes albopictus mosquitoes. The purpose of this study is to evaluate the effectiveness of fluid therapy and symptomatic management in patients with dengue viral fever. Methods: This retrospective observational study at the Department of Internal Medicine, Dhaka Medical College Hospital (DMCH), Bangladesh (July 2023–June 2024), included 160 dengue patients. Baseline clinical and laboratory data were recorded, and patients received oral, IV, or combined fluid therapy per WHO protocols. Outcomes included hemodynamic stabilization, laboratory changes, symptom improvement, complications, hospital stay, and final recovery. Data were analyzed with SPSS 26.0 using chi-square and ANOVA, with p < 0.05 considered significant. Results: In 160 dengue patients, most were febrile (70%). IV fluids were used in 55.6%, oral in 30%, and combined in 14.4%, with stabilization rates of 83.3%, 91.0%, and 95.6%. Hematocrit, platelets, and lactate improved significantly within 48 hours. Complications were low (plasma leakage 11.3%). Mean hospital stay was 4.6 days, and 96.9% achieved full recovery with no mortality. Conclusion: Effective and phase-appropriate fluid therapy combined with symptomatic management resulted in rapid stabilization and overwhelmingly favorable recovery outcomes in patients with dengue viral fever.